Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

PHASE4CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

June 30, 2013

Conditions
Infertility
Interventions
DRUG

Menotrophin

Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.

DRUG

Follitrophin alpha

Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.

DRUG

Cetrorelix

Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.

DRUG

Choriongonadotropin

10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.

DRUG

Progesterone

Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).

Trial Locations (8)

Unknown

Fertility Center Berlin, Berlin

Praxisklinik Sydow am Gendarmenmarkt, Berlin

Kinderwunschzentrum Dortmund, Dortmund

Universitätsklinikum Duesseldorf, Frauenklinik, Düsseldorf

Praxis für Kinderwunschbehandlung, Erlangen

NOVUM Zentrum, Essen

IVF Zentrum, Saar

Endokrinologikum Ulm, Ulm

Sponsors
All Listed Sponsors
collaborator

Ferring Arzneimittel GmbH

INDUSTRY

lead

Ferring Pharmaceuticals

INDUSTRY